Newsletters

Alliance E-News is the official newsletter of the Alliance for Clinical Trials in Oncology. The periodic newsletter focuses on current information about the Alliance, its policies and procedures, Group meetings and activities, and other topics of interest to Alliance members and others in the cancer research community. Press releases can also be found on this page.

• 2025
• April
  • Optimizing the When and How of Cancer Treatment: The Mission of PBTP
• March
  • FDA Approves Drug for Patients with Previously Treated Advanced Neuroendocrine Tumors Based on Results from Alliance CABINET Trial
  • Spotlight on Alliance Trials
    A022101 (Limited metastatic colorectal cancer)
    A022104 (Advanced rectal cancer)
    A031701 (Invasive bladder cancer)
    A031803 (Non-muscular invasive bladder cancer)
    A032103 (Muscle invasive bladder cancer)
• Feburary
  • A Message from the NCTN Group Chairs: An Emphasis on the Importance of Research Funding
• January
  • Spotlight on Scientifc Annual Meeting: 2025 ASCO GI
  • Blood Test from Alliance Trial Guides Use of Anit-Inflammatory Drug to Lower Colon Cancer Recurrence Risk

• 2024
• December
  • Alliance Group Chair Year-End Message
  • Alliance Programs At-a-Glance Year-End Review
  • Alliance Holiday Office Closures
  • Spotlight on Scientific Annual Meetings: 2024 SABCS
  • Spotlight on Scientific Annual Meetings: 2024 ASH
  • New PROSPECT-Lung Trial Launches to Advance Treatment Options for Operable Non-Small Lung Cancer
  • Alliance Foundation Trials Phase III PATINA Study Shows Promise for Patients with HR+, HER2+ Metastatic Breast Cancer
• November

  • Dr. David Kozono Elected New Group Vice-Chair

• October

  • Alliance Group Statistician Co-Chairs Working Group Whose Recommendations Define "New Normal" Data Collection and Published in the Journal of the National Cancer Institute

  • MyeloMATCH Precision Medicine Trials in Myeloid Leukemias Open to Patient Enrollment Across the U.S. and Canada

  • 2024 Alliance Fall Hybrid Group Meeting Convenes October 30-November 1

  • Alliance Features Five Trials During National Breast Cancer Awareness Month
    A011801 (COMPASS HER2 RD/Breast Cancer)
    A012103 (Early-stage Triple Negative Breast Cancer)
    A071701 (Genomically-guided Treatment in Brain Metastases)
    A191901 (Optimizing Endocrine Therapy)
    A222101 (Preventing Paclitaxel-associated Neuropathy)
  • Alliance Appoints New Chief Operating Officer
• September
  • Alliance Appoints New Chief Operating Officer

  • Viewpoint: Radiation target nomenclature for lymphoma trials: consensus recommendations from the National Clinical Trials Network groups

  • Cancer Cooperative Group Leaders Propose a Re-engineering of the Nation's Correlative Science Program for Cancer

  • Spotlight on #ESMO24
  • Alliance Presents Final Results From Phase III CABINET Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors at ESMO 2024 and Published in New England Journal of Medicine
  • Alliance Presents Results From AMBASSADOR Trial for Patients with High-Risk Muscle-Invasive Bladder Cancer at ESMO 2024 and Published in New England Journal of Medicine

• August
  • Spotlight in Alliance Trials
    World Lung Cancer Day
    >> Alliance A021901
    >> Alliance A081801
    >> Alliance A082002
    >> Alliance A082101
    >> Alliance A151216
    >> Alliance A211901
  • Alliance Publications Committee: Transition and Progress
  • General News and Announcements
    >> Alliance Research in the News & Publications
    >> Call for Nominations: Richard L. Schilsky CALGB Achievement Award
    >> Call ofr Nominations: Charles G. Moertel Lectureship Award
    >> Call for Applications: Daniel J. Sargent, PhD Memorial Fellowship in Innovative Clinical Trial Design and Methods
  • PDF
• May
  • Updates on Precision Medicine Trials
    >> ALCHEMIST Trials
    David Kozono, MD, PhD - Study Chair, Alliance A151216
    Jacob Sands, MD - Study Chair, Alliance A081801   
    >> ComboMATCH Trials
    Ardaman Shergill, MD - Study Chair, Alliance EAY191-A6
    Geoffrey Shapiro, MD, PhD - Study Chair, Alliance EAY191-A3
  • Influencing New Standards of Cancer Care:
    VCU Massey Cancer Center MU-NCORP
    Asit Paul, MD, PhD - Site Principal Investigator for MU-NCORP Alliance Trials
  • Evolution of Cancer Research Advocacy in Alliance
    Patty Spears, Vernal Branch, and Jane Permlmutter
    Alliance Patient Advocate Committee Leadership
  • Spotlight in Alliance Trials
    National Bladder Cancer Awareness Month
    >> Alliance A031701
    >> Alliance A031702
    >> Alliance A031803
    >> Alliance A032002
    >> Alliance A032103
    National Brain Cancer Awareness Month
    >> Alliance A071401
    >> Alliance A071601
    >> Alliance A071701
    >> Alliance ABTC-1604
  • General News and Announcements
    >> Alliance NCTN/NCORP/AFT at 2024 ASCO
    >> Alliance Research in the News & Publications
    >> 2024 Spring Hybrid Group Meeting
    >> 2024 Giants of Cancer Care Inductees 
  • PDF
• March
  • Message From The Group Statistician
  • Breaking New Ground: Alliance Procedure-Based Therapy Program
  • Update: Alliance Participant Engagement Portal (PEP)
  • Spotlight on Alliance Trials
    >> Alliance A022004
    >> Alliance A022101
    >> Alliance A221805
    >> Alliance A031701
    >> Alliance A031803
    >> Alliance A032002
    >> Alliance A032103
  • General News and Announcements
    >> Alliance Research in the News & Publications
    >> 2024 Spring Hybrid Group Meeting
  • PDF
• January
  • Announcements
    >> Call for Nominations: Co-Chair, Alliance Publications Committee
    >> 2024 Alliance/AFT ASCO Abstract Submission Deadlines
    >> Alliance Foundation Special Allocation Funding Opportunity
  • Press Release
    >> Alliance Study Shows Positive Results for Patients with Muscle-invasvie Urothelial Carcinoma
    >> Haystack Oncology and Alliance Foundation Trials collaborate to use Haystack MRD™ technology in phase II clinical trial for unresectable stage III NSCLC (AFT-57)
  • Alliance in the News
    >> Clinical trial investigates how many months of immunotherapy are necessary to treat early-stage breast cancer (Alliance A012103 - OptimICE)
  •